{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:29:54Z","timestamp":1787063394820,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.biologicals.2008.06.002","type":"journal-article","created":{"date-parts":[[2008,8,4]],"date-time":"2008-08-04T09:54:56Z","timestamp":1217843696000},"page":"330-335","source":"Crossref","is-referenced-by-count":50,"title":["Virus inactivation by solvent\/detergent treatment using Triton X-100 in a high purity factor VIII"],"prefix":"10.1016","volume":"36","author":[{"given":"Peter L.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2008.06.002_bib1","unstructured":"Committee for Proprietary Medicinal Products, European Medicines Evaluation Agency. Note for guidance on plasma-derived medicinal products. CPMP\/BWP\/269\/95 rev 3; 2001."},{"key":"10.1016\/j.biologicals.2008.06.002_bib2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1046\/j.1537-2995.1985.25686071422.x","article-title":"Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations","volume":"25","author":"Horowitz","year":"1985","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2008.06.002_bib3","first-page":"147","article-title":"Virus safety of solvent\u2013detergent treated blood products","volume":"81","author":"Horowitz","year":"1993","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.biologicals.2008.06.002_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1423-0410.1984.tb00045.x","article-title":"Inactivation of hepatitis B and Hutchinson strain non-A, non-B viruses by exposure to Tween 80 and ether","volume":"46","author":"Prince","year":"1984","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2008.06.002_bib5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0140-6736(86)91101-3","article-title":"Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate","volume":"i","author":"Prince","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2008.06.002_bib6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1046\/j.1537-2995.2003.00496.x","article-title":"West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data","volume":"43","author":"Kreil","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2008.06.002_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/biol.1999.0236","article-title":"Resistance of vaccinia virus to inactivation by solvent\/detergent treatment of blood products","volume":"28","author":"Roberts","year":"2000","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2008.06.002_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1423-0410.2003.00275.x","article-title":"Effect of manufacturing process parameters on virus inactivation by solvent\u2013detergent treatment in a high-purity factor IX concentrate","volume":"84","author":"Roberts","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2008.06.002_bib9","unstructured":"Committee for Proprietary Medicinal Products, European Medicines Evaluation Agency. Note for guidance on virus validation studies. The design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP\/BWP\/268\/95; 1996."},{"issue":"Suppl. 1","key":"10.1016\/j.biologicals.2008.06.002_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1423-0410.1998.tb05473.x","article-title":"Virus inactivation by solvent\/detergent treatment and the manufacture of SD-plasma","volume":"74","author":"Horowitz","year":"1998","journal-title":"Vox Sang"},{"issue":"Suppl. 1","key":"10.1016\/j.biologicals.2008.06.002_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1423-0410.1998.tb05474.x","article-title":"Solvent\/detergent treatment of human plasma \u2013 a very robust method for virus inactivation. Validated virus safety of OCTAPLAST","volume":"74","author":"Biesert","year":"1998","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2008.06.002_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.V79.3.826.826","article-title":"Solvent\/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma","volume":"79","author":"Horowitz","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.biologicals.2008.06.002_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1423-0410.1987.tb02989.x","article-title":"Tri(n-butyl)phosphate\/detergent treatment of licensed therapeutics and experimental blood derivatives","volume":"52","author":"Edwards","year":"1987","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2008.06.002_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF01703243","article-title":"Ultrapure plasma factor VIII produced by anti-F VIIIc immunoaffinity chromatography and solvent\/detergent viral inactivation. Characterization of the \u2018Method M\u2019 process and Hemofil M antihemophilic factor (human)","volume":"63","author":"Griffiths","year":"1991","journal-title":"Ann Hematol"},{"key":"10.1016\/j.biologicals.2008.06.002_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1423-0410.2006.00772.x","article-title":"A minipool process for solvent\u2013detergent treatment of cryoprecipitate at blood centres using a disposable bag system","volume":"91","author":"Burnouf","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2008.06.002_bib16","first-page":"497","article-title":"Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma","volume":"11","author":"Kim","year":"2001","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.biologicals.2008.06.002_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0021-9673(01)01565-5","article-title":"Determination of Triton X-100 in plasma-derived coagulation factor VIII and factor IX products by reversed-phase high-performance liquid chromatography","volume":"946","author":"Karisson","year":"2002","journal-title":"J Chromatogr"},{"key":"10.1016\/j.biologicals.2008.06.002_bib18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1423-0410.2007.01016.x","article-title":"A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity","volume":"94","author":"Poelsler","year":"2008","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2008.06.002_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biologicals.2007.03.002","article-title":"Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent\/detergent-treated plasma","volume":"35","author":"Burnouf","year":"2007","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2008.06.002_bib20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2516.2007.01554.x","article-title":"Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up","volume":"13","author":"Mauser-Bunschoten","year":"2007","journal-title":"Haemophilia"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105608000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105608000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T08:12:48Z","timestamp":1588839168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105608000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S1045105608000560"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2008.06.002","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}